Methylation based AI classification of acute leukemia nature.com/articles/s4158…

Now out in print: Targeting DNA damage in ageing: towards supercharging DNA repair. New perspectives how we could tackle cancer and aging at their mechanistic root cause: nature.com/articles/s4157…

Our RAEFISH spatial transcriptomics technology is now published in Cell Cell! RAEFISH enables sequencing-free whole genome spatial transcriptomics at single molecule resolution. This work represents the first time that transcripts from more than 23,000 genes were

Improved effectors for CRISPRi/CRISPRa are developed following high-throughput screening of transcriptional domains go.nature.com/3NMu00N rdcu.be/eI28L

Published today in Science Magazine: a landmark study led by Microsoft scientists with partners, showing how AI-powered protein design could be misused—and presenting first-of-its-kind red teaming & mitigations to strengthen biosecurity in the age of AI.

Targeting DNA damage in ageing: towards supercharging DNA repair nature.com/articles/s4157… rdcu.be/eJIpr This Review in the October issue discusses approaches to pharmacologically mitigate adverse effects of DNA damage to delay ageing and prevent mutation-driven cancer

AI cancer driver mutation predictions are valid in real-world data | Nature Communications nature.com/articles/s4146…

For readers interested in finding out more about in vivo CAR-T therapies such as those at the centre of the $1.5 billion acquisition of Orbital Therapeutics by Bristol Myers Squibb today, here's a comprehensive review rdcu.be/eKnwV nature.com/articles/s4157…

Dissecting the impact of transcription factor dose on cell reprogramming heterogeneity using scTF-seq | Nature Genetics nature.com/articles/s4158…

FDA new drug approvals in Q3 2025 nature.com/articles/d4157… Q3 saw a welcome bolus of novel FDA drug approvals, with the 16 approvals matching the 16 approvals in total in the first half of the year, including the first drug for bronchiectasis nature.com/articles/d4157…

Programmable promoter editing for precise control of transgene expression go.nature.com/4h9wlR1

Science leader job in the UK 🤩

Our team designed a “dual-warhead” drug that links platinum to doxorubicin to tackle one of cancer’s toughest problems — chemoresistance. It keeps chemo inside cancer cells longer and boosts effectiveness. 🔗 rdcu.be/eLRl7

Are you a PhD student interested in machine learning and biology or health? Come do an internship with me, Ava Amini, Alex Lu, Lorin Crawford, or Kristen Severson at @msrne! Applications are due Dec 1: make sure you include a research statement! jobs.careers.microsoft.com/global/en/job/…

Predicting drug responses of unseen cell types through transfer learning with foundation models nature.com/articles/s4358…

📢 Excited to share the latest from our lab: we discovered a new synthetic-lethal vulnerability in cancer cells with APOBEC3A activity and its underlying mechanism 🔧🧩 -APOBEC3A induces DNA double-strand breaks🧬✂️🧬 - APOBEC3A shifts double-strand DNA break repair towards

🤔How do you design a promoter for stable titration of expression? 💡Try programmable promoter editing with DIAL! 📰Now published at Nature Biotechnology 🧵 [1/n] 🔗 below

A gene program dictionary of human cells biorxiv.org/content/10.110…

Proud to share that our staff published 44 papers in Sept, including in NEJM, The Lancet, JAMA Surgery, and Journal of Clinical Oncology, advancing India’s and the world’s fight against cancer through research and collaboration. ACTREC-TMC Tata Memorial Centre, Varanasi (MPMMCC & HBCH) Cancer Research Institute - ACTREC Homi Bhabha Cancer Hospital & Research Centre HBCHRC,VIZAG - TATA MEMORIAL CENTRE

🚀 Prophet v3 is out! AI that predicts how cells respond to genetic & chemical perturbations across readouts. Now scales to 1.9 M molecules + in vitro validation of melanoma-specific hits 🧬💊 📄 biorxiv.org/content/10.110… #AI #Biology #DeepLearning